Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon L Walmsley

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 11, 2013
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infectionDarrell H S Tan, Janet M Raboud, Rupert Kaul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 25, 2021
Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell RecoveryRodney K Rousseau, Sharon L Walmsley, Terry Lee, et al.
Plos One|September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trialDarrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
AIDS (London, England)|January 26, 2018
Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patientsCarmine Rossi, Sahar Saeed, Joseph Cox, et al.
AIDS Patient Care and Stds|July 25, 2012
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophyJordan E Lake, Grace A McComsey, Todd M Hulgan, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Antibodies (Basel, Switzerland)|April 27, 2026
SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIVSharon L Walmsley, Leif Erik Lovblom, Bryan Boyachuk, et al.
AIDS Care|November 12, 2013
The importance of motherhood in HIV-positive women of reproductive age in Ontario, CanadaV Logan Kennedy, Lena Serghides, Janet M Raboud, et al.
Mediators of Inflammation|July 4, 2014
Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trialTodd Hulgan, M Sean Boger, Diana H Liao, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 11, 2013
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infectionDarrell H S Tan, Janet M Raboud, Rupert Kaul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 25, 2021
Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell RecoveryRodney K Rousseau, Sharon L Walmsley, Terry Lee, et al.
Plos One|September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trialDarrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
AIDS (London, England)|January 26, 2018
Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patientsCarmine Rossi, Sahar Saeed, Joseph Cox, et al.
AIDS Patient Care and Stds|July 25, 2012
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophyJordan E Lake, Grace A McComsey, Todd M Hulgan, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Antibodies (Basel, Switzerland)|April 27, 2026
SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIVSharon L Walmsley, Leif Erik Lovblom, Bryan Boyachuk, et al.
AIDS Care|November 12, 2013
The importance of motherhood in HIV-positive women of reproductive age in Ontario, CanadaV Logan Kennedy, Lena Serghides, Janet M Raboud, et al.
Mediators of Inflammation|July 4, 2014
Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trialTodd Hulgan, M Sean Boger, Diana H Liao, et al.
Pageof 11